Searchable abstracts of presentations at key conferences on calcified tissues

ba0007p13 | (1) | ICCBH2019

Clinical implications of modeling the maturational spurt

Boeyer Melanie , Leary Emily , Sherwood Richard , Duren Dana

Objective: The treatment of many skeletal growth and/or developmental disorders often relies on a child’s biological maturity status, frequently determined by a skeletal maturity assessment. Rapid changes in the rate of skeletal maturation (i.e., the maturational spurt) during adolescence can significantly influence biological maturity status, affecting treatment type and timing as well as clinical outcomes. However, the chronological age at which peak maturational veloci...

ba0003oc6.3 | Osteoporosis treatment and the effects of physical activity | ECTS2014

Vitamin D is low in obesity, and this is due to greater volume of distribution

Walsh Jennifer S , Evans Amy L , Bowles Simon , Naylor Kim E , Gossiel Fatma , Jacques Richard , Schoenmakers Inez , Jones Kerry S , Eastell Richard

Low circulating levels of total 25-hydroxyvitamin D (25OHD) have been reported in obese people of different ethnicities in several countries. Low total 25OHD in obesity could be due to lower binding proteins (with normal free 25OHD), lower dietary intake or sunlight exposure, greater volume of distribution (pool size) or more rapid metabolic clearance.The aims of this study were to determine if free 25OHD and 1,25-dihydroxyvitamin D (1,25(OH)2...

ba0001pp85 | Bone development/growth and fracture repair | ECTS2013

The retention and bioactivity of rhBMP-2 released from a bisphosphonate-linked hyaluronan-based hydrogel

Hulsart-Billstrom Gry , Yuen Pik-Kwan , Marsell Richard , Hilborn Jons , Larsson Sune , Ossipov Dmitri

Introduction: There are several disadvantages with the present carriers used in rhBMP-2 products including risk for immunological response, inefficient release and poor handling properties. Our aim was to examine the release of rhBMP-2 from a bisphosphonate-linked hyaluronan hydrogel with the hypothesis that it would cause a slower release.Methods: Triplicates of hydrogels with rhBMP-2 and with (HA-BP) or without (HA) bisphosphonate were prepared, after ...

ba0003oc6.5 | Osteoporosis treatment and the effects of physical activity | ECTS2014

The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal women with rsteoporosis: The TRIO study

Gossiel Fatma , Hoyle Christopher , McCloskey Eugene , Walsh Jennifer , Peel Nicola , Eastell Richard

Bisphosphonates are used to treat bone disease characterised by increased bone resorption by inhibiting the activity of mature osteoclasts, resulting in decreased bone turnover. Bisphosphonates may reduce the population of osteoclast precursor cells (OPCs). Our aims were to investigate the effect of bisphosphonates on i) OPCs and ii) bone turnover in postmenopausal women with osteoporosis compared with healthy premenopausal women. Participants were 62 postmenopausal women (mea...

ba0003pp125 | Cell biology: osteoblasts and bone formation | ECTS2014

The significance of Bcl-2-associated athanogene-1 (BAG-1)-mediated protein interactions in osteoblast development

Greenhough Joanna , Papadakis Emmanouil , Cutress Ramsey , Townsend Paul , Oreffo Richard , Tare Rahul

BAG-1 interacts with diverse proteins including heat shock proteins (HSC70/ HSP70) and nuclear hormone receptors to modulate cell proliferation, differentiation and apoptosis. We have shown that bone marrow stromal cells (BMSCs) of Bag-1+/− female mice display reduced BMP-2-directed osteogenic differentiation potential. Estradiol binds to estrogen receptors (ERs) and is functionally involved in BMP-directed osteogenic differentiation of osteoprogenito...

ba0003pp306 | Osteoporosis: treatment | ECTS2014

The effect of bisphosphonate treatment on sclerostin levels in postmenopausal osteoporosis: the TRIO study

Gossiel Fatma , Naylor Kim , McCloskey Eugene , Peel Nicola , Walsh Jennifer , Paggiosi Margaret , Eastell Richard

Treatment of postmenopausal osteoporosis with bisphosphonates reduces bone resorption and formation. Sclerostin, an osteocyte regulator of bone formation may be involved in these changes. Some studies have reported an increase in sclerostin associated with bisphosphonate treatment while others have reported a decrease. The aims were to determine the effect of bisphosphonates on i) circulating sclerostin and ii) PINP in postmenopausal women with osteoporosis. We studied 92 post...

ba0003pp330 | Osteoporosis: treatment | ECTS2014

Determinants of bone turnover marker response to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study

Naylor Kim , Paggiosi Margaret , Gossiel Fatma , McCloskey Eugene , Peel Nicola , Walsh Jennifer , Eastell Richard

Three oral bisphosphonates ibandronate, alendronate, and risedronate are commonly used for the treatment of osteoporosis but they have not previously been compared in the same study. Our aim was to identify determinants of change in bone turnover markers (BTM) in response to these bisphosphonates in a 2-year randomised parallel group trial. We recruited 171 postmenopausal osteoporotic women (<85 years) who were randomised to receive ibandronate (150 mg monthly), alendronat...

ba0003pp363 | Other diseases of bone and mineral metabolism | ECTS2014

Sustained efficacy and tolerability in infants and young children with life-threatening hypophosphatasia treated with asfotase alfa

Whyte Michael , Simmons Jill , Lutz Richard , Vallee Marc , Melian Agustin , Odrljin Tatjana , Bishop Nick

Background: Hypophosphatasia (HPP) results from inactivating mutation(s) in the gene for tissue non-specific alkaline phosphatase (TNSALP). Substantial improvement has been reported in skeletal mineralization and physical function in patients (pts) with life-threatening perinatal and infantile HPP treated for 48 weaks with asfotase alfa, a bone-targeted recombinant human TNSALP.Objective: To evaluate long-term efficacy and tolerability of asfotase alfa i...

ba0004p122 | (1) | ICCBH2015

Phalangeal microgeodic disease: A rare cause of painful swollen toes

Govindan Ranjith , Green Ruth , Dyankova-Peeva Daniela , Keen Richard , Jacobs Benjamin

A healthy 8-year-old girl of Nigerian origin, presented in January 2014 with a 2 month history of progressive pain and swelling of the right 2nd, 3rd and 4th toe. There was no preceding trauma or illness. Those toes were swollen, tender and cold to touch, with bluish skin discoloration (Figure 1).She had normal peripheral pulses. Her inflammatory markers were normal, as was haemoglobin electrophoresis. A Doppler ultrasoun...

ba0004p130 | (1) | ICCBH2015

Chronic recurrent multifocal osteomyelitis: the value of whole-body MRI in a series of 34 children

Jacobs Benjamin , Brown Mathew , Guha Ananya , Alexandrou Dion , Paul O'Donnell , Keen Richard

Objectives: To assess the role of whole-body MRI in the diagnosis and management of chronic recurrent multifocal osteomyelitis (CRMO) is a benign and non-infective auto-inflammatory bone disorder characterised by multiple and recurrent inflammatory bone lesions. No universal diagnostic criteria exist.Methods: Retrospective review of CRMO cases diagnosed at this hospital between 2008 and 2014. Cases were identified from patient records and clinical inform...